Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Satsuma Pharmaceuticals, Inc. : Announces Closing of Initial Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/17/2019 | 04:02pm EDT

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company's previously announced initial public offering of 5,500,000 shares of common stock at a public offering price of $15.00 per share, which does not include the exercise by the underwriters of their option to purchase up to an additional 825,000 shares of common stock. Aggregate gross proceeds to the Company were approximately $82.5 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by Satsuma. Satsuma's common stock is listed on The Nasdaq Global Market under the ticker symbol "STSA."

Credit Suisse, SVB Leerink and Evercore ISI acted as joint book-running managers for the offering.

Registration statements relating to the shares sold in this offering were declared effective by the Securities and Exchange Commission on September 12, 2019. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY, 10010, by telephone at 1-800-221-1037 or by e-mail: usa.prospectus@credit-suisse.com; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by email at syndicate@svbleerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at 1-888-474-0200 or by e-mail: ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Contact:
Investors or Media
Tom O'Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com

Cision
View original content:http://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-inc-announces-closing-of-initial-public-offering-300920112.html

SOURCE Satsuma Pharmaceuticals, Inc.


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
10:35aLOGITECH INTERNATIONAL S A : Own Your Space With a Modern Mouse That Fits Your Lifestyle
PU
10:35aAurora Solar Technologies Increases Intellectual Property Portfolio and Announces Key R&D Grant
NE
10:35aGODEWIND IMMOBILIEN AG : Correction of a release from 21/10/2019 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
10:34aFACEBOOK : ECB's Costa says banks need to act fast as tech firm rivalry looms
RE
10:34aTHAI AIRWAYS INTERNATIONAL PCL : President leaves for Japan on final state tour
AQ
10:34aKDA : Announces Closing of Private Placement and Completes Debt Settlement
AQ
10:34aKDA : Groupe KDA Annonce la Cloturee D'un Placement Prive et Complete un Reglement de Dette
AQ
10:34aSUMITOMO : Taiwan to sue Japanese company for deadly train accident
AQ
10:34aXDD Expands Managed Review Offering with Opening of New Review Center in Indianapolis, IN
GL
10:34aKBRA Assigns Preliminary Ratings to Flagstar Mortgage Trust 2019-1INV (FSMT 2019-1INV)
BU
Latest news "Companies"